How to access Rybrevant from India — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumour carries an EGFR exon 20 insertion (or, in newer indications, specific EGFR-mutant NSCLC in combination regimens) may receive a prescription for Rybrevant (amivantamab) from their treating medical oncologist. Rybrevant is FDA-approved, developed by Janssen (Johnson & Johnson), and is a fully human EGFR/MET bispecific antibody addressing a molecular subset that historically has responded poorly to standard EGFR tyrosine kinase inhibitors. In India, Rybrevant is not yet broadly registered for routine pharmacy dispensing, which is why your oncologist may be navigating a named-patient import pathway with you.
This guide explains the legal pathway, what your physician needs to provide, typical timelines, and where Reserve Meds fits in.
The clinical situation
Rybrevant targets both EGFR and MET, with mechanisms including ligand-blocking, receptor downregulation, and antibody-dependent cell-mediated cytotoxicity. Administration is intravenous on a weight-based schedule — a split first-dose infusion followed by weekly dosing for four weeks, then every two weeks. Infusion-related reactions are common on the first cycle and require premedication and infusion-rate management; subsequent doses are generally better tolerated. Subcutaneous formulations are in evolving approval phases; check current labelling. Eligibility anchors to a confirmed EGFR exon 20 insertion (or specified co-mutation pattern in newer combination indications) on validated molecular testing. Your oncologist will confirm the molecular result and plan the infusion-reaction and skin-toxicity management cadence.
Is Rybrevant legally importable into India?
Yes — via the Central Drugs Standard Control Organisation (CDSCO) Personal Use / Named-Patient import framework, which permits a treating physician to import a medicine not yet locally registered when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent alternative is routinely available, (c) the physician accepts clinical responsibility, and (d) chain of custody through a licensed importer is documented. CDSCO issues a personal-use licence keyed to the individual patient and a specified quantity consistent with the infusion plan.
How the pathway works, step by step
- Consultation with your treating medical oncologist. EGFR exon 20 confirmation, prior-therapy documentation, performance-status assessment, and clinical rationale letter.
- Molecular-testing confirmation. NGS report documenting EGFR exon 20 insertion.
- CDSCO personal-use import application. Your physician or the importing licensed pharmacy files the dossier including rationale, patient reference, and infusion plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Rybrevant from authorised distribution under DSCSA.
- Cold-chain shipment. Rybrevant ships with validated temperature control to the nominated hospital pharmacy.
- First infusion and ongoing cadence. The oncology team administers with appropriate premedication and infusion-reaction management.
What documentation your physician needs
- Clinical rationale letter confirming diagnosis, EGFR exon 20 molecular status (or combination-indication rationale), prior-therapy sequence, and Rybrevant as the indicated treatment
- Verification of NMC / MCI registration
- Molecular testing (NGS tissue or plasma)
- Patient identifier (anonymised reference where possible)
- Dosing and infusion-reaction management plan
Reserve Meds provides a physician documentation kit bundling the CDSCO templates reviewers expect to see.
Costs and timing
Rybrevant's US cash-pay reference cost is weight-based; for a typical 60–70 kg patient the indicative 2026 monthly maintenance cost sits in the range of roughly USD 18,000–23,000, with a higher burden during the weekly loading phase. International logistics, CDSCO documentation handling, importer-of-record fees, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. These figures are indicative, not guaranteed.
Indicative timing — not guaranteed — for first infusion after cohort intake opens is approximately 14–28 days from the moment a complete CDSCO application is submitted.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A culturally-aware note: Indian NSCLC patients often travel from tier-2 and tier-3 cities to metro cancer centres. Our coordination is designed around that travel pattern; documentation flows electronically and shipment is directed to whichever tertiary pharmacy your oncologist nominates.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and CDSCO review, keyed to the EGFR exon 20 or combination-therapy rationale.
- Logistics. Cold-chain shipment to the nominated hospital pharmacy with importer-of-record handling.
- Concierge case lead. A named point of contact for your family and your oncology team.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Can Rybrevant be combined with Lazcluze (lazertinib)? Rybrevant is approved in combination with lazertinib for certain EGFR-mutant NSCLC populations in the US; your oncologist will determine the appropriate regimen and we coordinate the combination where relevant.
My tumour has a common EGFR mutation, not exon 20 — is Rybrevant right? Your oncologist will assess. Rybrevant has an expanded role in EGFR-mutant NSCLC in combination, but the specific regimen depends on the molecular profile and prior lines.
What about skin and nail toxicity? EGFR-targeted therapies commonly cause dermatological adverse events; a proactive skin-care regimen and early dermatology referral are standard. Your team will manage.
Will insurance cover this? Cash-pay is the default for named-patient imports. Some Indian private insurers consider case-by-case reimbursement for molecular-directed oncology; we supply documentation but do not process claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Rybrevant coordination.
Add me to the Rybrevant waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.